A pliable ERĪ± cistrome evades therapy
Crossref DOI link: https://doi.org/10.1038/s41556-020-0528-6
Published Online: 2020-05-18
Published Print: 2020-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wu, Xiaoli S.
Vakoc, Christopher R.
Text and Data Mining valid from 2020-05-18
Version of Record valid from 2020-05-18
Article History
First Online: 18 May 2020
Competing interests
: C.R.V. has received funding from Boehringer Ingelheim and Syros Pharmaceuticals and is an advisor to KSQ Therapeutics.